ClinicalTrials.gg
Not yet recruitingNCT06849895Updated Feb 27, 2025

Real-World Study of Myopia Prevention and Control in Children

An observational study in Myopia, Refractive Errors and Children, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15,000
Ages
6 Years to 12 Years
Sex
All
01

Study summary

This prospective, school-based cohort study aims to enroll approximately 15,000 primary school students from multiple districts in Shanghai, China and to observe the outcomes on myopia prevention and control in children with varying refractive status (including sufficient hyperopia reserve, relative insufficiency in hyperopia reserve, pre-myopia and myopia) who are exposed to a school-based categorized and integrated interventions strategy in real-world settings.

The primary objective of this study is to observe the change in the incidence and prevalence of myopia as well as the the progression of myopia among primary school students population under a school-based interventions, including increasing outdoor activities and wearing special designed optical lenses. The second objective is to identify factors influencing the outcomes and assess the compliance of different intervention methods. Additionally, a cost-effectiveness analysis will be conducted to assess the implementation process, providing technical solutions and operational models for wider application.

02

Conditions studied

  • Myopia
  • Refractive Errors
  • Children
  • Cohort

Keywords

  • myopia
  • premyopia
  • outdoor activities
  • myopia prevention
  • myopia control
  • children
  • compliance
  • defocus optical lenses
03

In context

Myopia

1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.

This study's planned enrollment of 15,000 is above the median of 150 across 204 observational studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 66 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All students in the enrolled schools can participate in the project and receive tiered interventions after obtaining informed consent from their guardians. After professional examination, students with conditions such as strabismus, amblyopia, other significant ocular abnormalities, systemic diseases, or those currently undergoing other myopia interventions will generally not be fitted with specially designed myopia control spectacles.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All students from the enrolled schools;
  2. Participants must be able to cooperate with and complete all required ophthalmic examinations;
  3. Written must be obtained from their parents or legal guardians.

Exclusion criteria

Exclusion Criteria:

  1. Ocular abnormalities (e.g., strabismus, amblyopia, or other significant eye diseases);
  2. Systemic diseases that may affect ocular health;
  3. Current participation in other myopia intervention programs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Sufficient hyperopia reserve

    Cycloplegic spherical equivalence is higher than the recommended values and falls within the normal range for the corresponding age group.

  • Relative insufficiency in hyperopia reserve

    Cycloplegic spherical equivalence is greater than +0.75 diopters but below the recommended value for the corresponding age group.

  • Premyopia

    -0.50 diopters \< cycloplegic spherical equivalence ≤ +0.75 diopters

  • Myopia

    Cycloplegic spherical equivalence ≤ -0.50 diopters

06

What researchers measure

Primary outcomes

  1. Myopia incidence

    Myopia incidence

    Time frame: Assessed at 12 months, 24 months, and 36 months post-baseline.

  2. Myopia progression

    Myopia progression in myopic participants

    Time frame: Assessed at 12 months, 24 months, and 36 months post-baseline.

Secondary outcomes

  1. Myopic shift

    Change of spherical equivalence and axial length

    Time frame: Assessed at 12 months, 24 months, and 36 months post-baseline.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06849895
Lead sponsor
Shanghai Eye Disease Prevention and Treatment Center
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Feb 28, 2025 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Feb 27, 2025

Study contacts

Xiangui He, PhD
Contact
xianhezi@163.com
+86 021-62717733

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion